Vascular endothelial growth factor receptor 2 expression and immunotherapy efficacy in non-small cell lung cancer.

ABSTRACT: It is unclear whether tumor vascular endothelial growth factor receptor 2 expression affects the therapeutic efficacy of immune-checkpoint inhibitors and antiangiogenic agents. This retrospective, multicenter study included patients with advanced non-small cell lung cancer who were treated with immune-checkpoint inhibitors. We constructed tissue microarrays and performed immunohistochemistry with an anti-vascular endothelial growth factor receptor 2 antibody. We analyzed immune and tumor cell staining separately in order to determine their correlation with the objective response rate, progression-free survival, and overall survival in patients receiving immune-checkpoint inhibitors. Of 364 patients, 37 (10%) expressed vascular endothelial growth factor receptor 2 in immune cells and 165 (4

SUBMITTER: Nakahama K 

PROVIDER: S-EPMC9459341 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature